Clinical Trials Browser

Completed × Tumor Lysis Syndrome × Other hematologic neoplasm × Clear all

Sleepiness, Arrhythmias, Cardiac, Cataract, Confusion, Coronary Artery Disease, Digestive System Diseases, Dizziness, Fatigue, Heart Failure, Hemorrhage, Hypersensitivity, Hypotension, Orthostatic, Hypothyroidism, Infections, Lymphoma, Peripheral Nervous System Diseases, Seizures, Thromboembolism, Tumor Lysis Syndrome, Neoplasms, Second Primary, Lung Diseases, Interstitial, Renal Insufficiency, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Teratogenesis

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Phase 3 Completed

120 enrolled 14 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01200485 2020-01-31

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Phase 2 Completed

55 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT00186940 2017-04-25

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

Completed

16 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome, Hyperuricemia

NCT01724528 2014-11-03

FLORENCE

Phase 3 Completed

346 enrolled 16 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome

NCT00628628 2013-08-01

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Phase 2 Completed

82 enrolled 6 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Tumor Lysis Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hyperuricemia

NCT00360438 2012-08-01

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

Phase 1/2 Completed

18 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Phase 3 Completed

280 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

NCT00230217 2009-03-30

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Phase 4 Completed

94 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms, Recurrence, Tumor Lysis Syndrome, Hyperuricemia

Clinical Trials

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

FLORENCE

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy